围手术期全身治疗在膀胱癌中不断演变的作用。
完整摘要 · 中文译文
肌层浸润性膀胱癌的治疗格局最近因两项关于围手术期恩诺单抗维多汀联合帕博利珠单抗的关键3期研究而发生了转变。这些试验已证明，与既往标准治疗相比，无事件生存期和总生存期均有显著改善，标志着肌层浸润性膀胱癌患者管理进入了一个不再由顺铂合格性定义的新时代。目前的焦点正转向识别更多新的治疗靶点以进一步改善结局，以及寻求优化肿瘤控制和生存者管理的反应指导性治疗路径。
完整摘要 · 英文原文
The treatment landscape for muscle-invasive bladder cancer has recently been transformed by two key phase 3 studies of perioperative enfortumab vedotin plus pembrolizumab. These trials have demonstrated significant improvements in event-free survival and overall survival compared with the previous standards of care, marking a new era in the management of patients with muscle-invasive bladder cancer that is no longer defined by cisplatin eligibility. The focus is now shifting toward the identification of additional novel therapeutic targets for further improved outcomes as well as response-guided treatment pathways seeking to optimize both cancer control and survivorship.